$0.08
0.00% day before yesterday
Nasdaq, Jun 26, 03:30 pm CET
ISIN
CA45783P1027
Symbol
INNPF
Sector
Industry

InnoCan Pharma Stock price

$0.08
-0.06 42.86% 1M
-0.08 48.98% 6M
-0.08 48.98% YTD
-0.12 59.90% 1Y
-0.34 80.99% 3Y
-0.11 58.48% 5Y
-0.41 83.67% 10Y
-0.41 83.67% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
+0.00 0.00%
ISIN
CA45783P1027
Symbol
INNPF
Sector
Industry

Key metrics

Basic
Market capitalization
$48.0m
Enterprise Value
$42.9m
Net debt
$-5.1m
Cash
$6.4m
Shares outstanding
291.2m
Valuation (TTM | estimate)
P/E
- | -
P/S
1.57 | -
EV/Sales
1.41 | -
EV/FCF
negative
P/B
4.97
Financial Health
Equity Ratio
55.80%
Return on Equity
-35.49%
ROCE
5.54%
ROIC
7.89%
Debt/Equity
0.28
Financials (TTM | estimate)
Revenue
$30.5m | -
EBITDA
$490.0k | -
EBIT
$454.0k
Net Income
$-650.0k | -
Free Cash Flow
$-480.0k
Growth (TTM | estimate)
Revenue
61.47% | -
EBITDA
113.21% | -
EBIT
112.11%
Net Income
87.50% | -
Free Cash Flow
86.32%
Margin (TTM | estimate)
Gross
89.61%
EBITDA
1.61% | -
EBIT
1.49%
Net
-2.13% | -
Free Cash Flow
-1.58%
More
EPS
$0.00
FCF per Share
$0.00
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is InnoCan Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Financial data from InnoCan Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
30 30
61% 61%
100%
- Direct Costs 3.16 3.16
40% 40%
10%
27 27
64% 64%
90%
- Selling and Administrative Expenses 36 36
91% 91%
118%
- Research and Development Expense 1.31 1.31
19% 19%
4%
0.49 0.49
113% 113%
2%
- Depreciation and Amortization 0.04 0.04
0% 0%
0%
EBIT (Operating Income) EBIT 0.45 0.45
112% 112%
1%
Net Profit -0.65 -0.65
88% 88%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about InnoCan Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

InnoCan Pharma Corp. operates as a pharmaceutical tech company. Its segments include: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science. It involves two drug delivery technologies: LPT CBD- loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative and self-care products to promote a healthier lifestyle. The company was founded in October 2017 and is headquartered in Alberta, Canada.

Head office Canada
CEO Iris Bincovich
Founded 2018
Website innocanpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today